[HTML][HTML] Potential therapeutic options for COVID-19: an update on current evidence
Abstract SARS-CoV-2, a novel coronavirus, is the agent responsible for the COVID-19
pandemic and is a major public health concern nowadays. The rapid and global spread of …
pandemic and is a major public health concern nowadays. The rapid and global spread of …
Interleukin‐6 blocking agents for treating COVID‐19: a living systematic review
L Ghosn, R Assi, T Evrenoglou… - Cochrane database …, 2023 - cochranelibrary.com
Background It has been reported that people with COVID‐19 and pre‐existing
autoantibodies against type I interferons are likely to develop an inflammatory cytokine storm …
autoantibodies against type I interferons are likely to develop an inflammatory cytokine storm …
[HTML][HTML] Management of hospitalised adults with coronavirus disease 2019 (COVID-19): a European Respiratory Society living guideline
JD Chalmers, ML Crichton… - European respiratory …, 2021 - Eur Respiratory Soc
Introduction Hospitalised patients with coronavirus disease 2019 (COVID-19) as a result of
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection have a high …
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection have a high …
[HTML][HTML] The role of cytokines and chemokines in severe acute respiratory syndrome coronavirus 2 infections
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has resulted in countless
infections and caused millions of deaths since its emergence in 2019. Coronavirus disease …
infections and caused millions of deaths since its emergence in 2019. Coronavirus disease …
[HTML][HTML] Respiratory sequelae of COVID-19: pulmonary and extrapulmonary origins, and approaches to clinical care and rehabilitation
Although the exact prevalence of post-COVID-19 condition (also known as long COVID) is
unknown, more than a third of patients with COVID-19 develop symptoms that persist for …
unknown, more than a third of patients with COVID-19 develop symptoms that persist for …
[HTML][HTML] Disulfiram inhibits neutrophil extracellular trap formation and protects rodents from acute lung injury and SARS-CoV-2 infection
Severe acute lung injury has few treatment options and a high mortality rate. Upon injury,
neutrophils infiltrate the lungs and form neutrophil extracellular traps (NETs), damaging the …
neutrophils infiltrate the lungs and form neutrophil extracellular traps (NETs), damaging the …
Update June 2022: management of hospitalised adults with coronavirus disease 2019 (COVID-19): a European Respiratory Society living guideline
N Roche, ML Crichton, PC Goeminne… - European respiratory …, 2022 - Eur Respiratory Soc
Since the identification of SARS-CoV-2 at the end of 2019, the coronavirus disease 2019
(COVID-19) pandemic has affected more than 410 million people worldwide and killed …
(COVID-19) pandemic has affected more than 410 million people worldwide and killed …
[HTML][HTML] Passive immunotherapy against SARS-CoV-2: from plasma-based therapy to single potent antibodies in the race to stay ahead of the variants
The COVID-19 pandemic is now approaching 2 years old, with more than 440 million people
infected and nearly six million dead worldwide, making it the most significant pandemic …
infected and nearly six million dead worldwide, making it the most significant pandemic …
[HTML][HTML] Monoclonal antibodies in the management of asthma: Dead ends, current status and future perspectives
Patients with moderate-to-severe asthma may now be treated using a variety of monoclonal
antibodies that target key inflammatory cytokines involved in disease pathogenesis. Existing …
antibodies that target key inflammatory cytokines involved in disease pathogenesis. Existing …
[HTML][HTML] The IL-1 cytokine family as custodians of barrier immunity
Abstract The interleukin-1 (IL-1) family of cytokines and receptors are implicated in the
functioning of innate and adaptive immunity and the genesis of inflammation. They are …
functioning of innate and adaptive immunity and the genesis of inflammation. They are …